Orphan drugs for the treatment of hairy cell leukemia

Bibliography

• Swerdlow SH, Campo E, Harris NL, editors. WHO classification of tumours of haematopoietic and lymphoid tissues IARC. IARC Press; Lyon: 2008
   Google Scholar
• Robak T. Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chemistry 2009;16:2212-34
   PubMedGoogle Scholar
• Matutes E. Novel and emerging drugs for rarer chronic lymphoid leukaemias. Curr Cancer Drug Targets 2012;12:484-504
   PubMed Web of Science ®Google Scholar
• Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol 2011;29:583-90
   Google Scholar
• Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy cell leukaemia. Best Pract Res Clin Haematol 2003;16:41-56
   PubMed Web of Science ®Google Scholar
• Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico -pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15:184-6
   PubMed Web of Science ®Google Scholar
• Robak T. Hairy cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011;37:3-10
   PubMed Web of Science ®Google Scholar
• Bouroncle BA, Wiseman BK, Doen CA. Leukemic reticuloendotheliosis. Blood 1958;13:609-30
   PubMed Web of Science ®Google Scholar
• Mercieca J, Matutes E, Moskovic E, Massive abdominal lymphadenopathy in hairy cell leukaemia: a report of 12 cases. Br J Haematol 1992;82:547-54
   Google Scholar
• Mercieca J, Matutes E, Emmett E, 2-Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. Br J Haematol 1996;93:409-11
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Matutes E, Morilla R, The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica 2004;89:303-8
   PubMed Web of Science ®Google Scholar
• Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol. Oncol. Clin. North Am 2006;20:1051-63
   PubMed Web of Science ®Google Scholar
• Falini B, Tiacci E, Liso A, Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004;363:1869-70
   PubMed Web of Science ®Google Scholar
• Miranda RN, Briggs RC, Kinney MC, Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol 2000;13(12):1308-14
   Google Scholar
• Hockley S, Morgan GJ, Leone PE, High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia 2011;25:1189-92
   PubMed Web of Science ®Google Scholar
• Forconi F, Sozzi E, Cencini E, Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood 2009;114:4696-702
   PubMed Web of Science ®Google Scholar
• Hockley SL, Giannouli S, Morilla A, Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol 2010;148:666-9
   PubMed Web of Science ®Google Scholar
• Basso K, Liso A, Tiacci E, Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med 2004;199:59-68
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15
   PubMed Web of Science ®Google Scholar
• Blombery PA, Wong SQ, Hewitt CA, Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica 2012;97:780-3
   PubMed Web of Science ®Google Scholar
• Andrulis M, Penzel R, Weichert W, Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012; Epub ahead of print
   Google Scholar
• Schnittger S, Bacher U, Haferlach T, Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 2012;119:3151-4
   PubMed Web of Science ®Google Scholar
• Xi L, Arons E, Navarro W, Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330-3
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, Long-term follow-up of 233 patients with hairy cell leukaemia treated initially with pentostatin or cladribine at a median of 16 years. Br J Haematol 2009;145:733-40
   PubMed Web of Science ®Google Scholar
• Grever M, Kopecky K, Foucar MK, Randomized comparison of pentostatin versus interferon alpha in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-82
   PubMed Web of Science ®Google Scholar
• Cheson BD, Sorensen JM, Montello MJ, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-15
   PubMed Web of Science ®Google Scholar
• Goodman RG, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891-6
   PubMed Web of Science ®Google Scholar
• Maloisel F, Benboubker L, Gardembas M, Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003;17:45-51
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK, Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981-6
   PubMed Web of Science ®Google Scholar
• Rafel M, Cervantes F, Beltran JM, Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000;88:352-7
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, Piro LD. Long term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998;92:1918-26
   PubMed Web of Science ®Google Scholar
• Arons E, Suntum T, Stetler-Stevenso M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009;114:4687-95
   PubMed Web of Science ®Google Scholar
• Coad J, Matutes E, Catovsky D. Splenectomy in lymphoproliferative disorders. A report on 70 cases and review of the literature. Leuk Lymphoma 1993;10:245-64
   PubMed Web of Science ®Google Scholar
• Matutes E, Catovsky D. The role of splenectomy in hairy cell leukemia. Chapter 10 In: Tallman M, Polliack A, editors. Hairy cell leukemia. Harwood Academic Publishers; 2000. p. 127-39
   Google Scholar
• Quesada JR, Reuben J, Manning JT, Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 1984;310:15-18
   PubMed Web of Science ®Google Scholar
• Golomb H, Fefer D, Golde H, Sequential evaluation of alpha-2b interferon treatment in 128 patients with hairy cell leukemia. Semin Oncol 1987;14:13-17
   PubMed Web of Science ®Google Scholar
• Golomb HM, Fefer D, Golde H, Report of a multiinstutional study of 193 patients with hairy cell leukemia treated with interferon alpha 2b. Semin Oncol 1988;15:7-9
   PubMed Web of Science ®Google Scholar
• Castaigne S, Sigaux F, Degos G, Flandrin G. Hairy cell leukemia. Follow-up after interferon treatment. Nouv Rev Fr Hematol 1989;31:321-5
   PubMedGoogle Scholar
• Berman E, Heller G, Kempin S, Incidence of response and long term follow up in patients treated with recombinant interferon-alpha-2b. Blood 1990;75:839-45
   PubMed Web of Science ®Google Scholar
• Rai K, Davey F, Peterson B, Recombinant alpha-2b interferon in therapy of previously untreated hairy cell leukemia. Long term results of a study by the Cancer and Leukemia Group B. Leukemia 1995;9:1116-20
   PubMed Web of Science ®Google Scholar
• Golomb HM. Hairy cell leukaemia. Treatment successes in the past 25 years. J Clin Oncol 2008;26:2607-9
   PubMed Web of Science ®Google Scholar
• Marotta G, Frassoldati A, Zinzani P, Italian Cooperative group for HCL (ICGHCL). Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. Eur J Haematol 2006;77(2):109-13
   Google Scholar
• Spiers AS, Parekh SL, Bishop MB. Hairy cell leukaemia: induction of complete remission with pentostatin (2’-deoxycoformycin). J Clin Oncol 1984;2:1336-42
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leucemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117-21
   PubMed Web of Science ®Google Scholar
• Seymour JF, Talpaz M, Kurzrock R. Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha resistant hairy cell leukemia: 7 year follow-up. Leukemia 1997;11:42-7
   PubMed Web of Science ®Google Scholar
• Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989;7:168-72
   PubMed Web of Science ®Google Scholar
• Johnston JB, Eisenhauer E, Corbett WE, Efficacy of 2´deoxycoformycin in hairy cell leukemia. A study of the National Cancer Institute of Canada Clinical trials Group. J Natl Cancer Inst 1988;80:765-9
   PubMed Web of Science ®Google Scholar
• Ho AD, Thaler J, Mandelli F, Response to pentostatin in hairy cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer. J Clin Ocol 1989;7:1533-8
   PubMed Web of Science ®Google Scholar
• Ribeiro P, Bouaffia F, Peaud PY, Lond term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999;88:65-71
   Google Scholar
• Cassileth PA, Cheuvart B, Spiers ASD, Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991;9:243-6
   PubMed Web of Science ®Google Scholar
• Grem J, King SA, Cheson BD. Pentostatin in hairy cell leukemia. Treatment by the exemption mechanism. J Natl Cancer Inst 1989;81:448-53
   PubMed Web of Science ®Google Scholar
• Golomb HM, Dodge R, Mick R, Pentostatin treatment of hairy cell leukemia patients who fail initial therapy with recombinant alpha-interferon. A report of CALGB study 8515. Leukemia 1994;8:2037-40
   PubMed Web of Science ®Google Scholar
• Catovsky D, Matutes E, Garcia Talavera JG, Long term results with 2´deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994;14(Suppl 1):109-13
   PubMed Web of Science ®Google Scholar
• Robak T, Błasinska-Morawiec M, Błonski J, 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62(1):49-56
   PubMed Web of Science ®Google Scholar
• Bastie JN, Cazals-Hatem D, Daniel M-T, Five years follow-up after 2-chlorodeoxyadenosine treatment in thirty patients with hairy cell leukemia. Evaluation of minimal residual disease and CD4+ lymphopenia after treatment. Leuk Lymphoma 1999;35:555-65
   PubMed Web of Science ®Google Scholar
• Lauria F, Rondelli D, Zinzani PL, Long lasting complete remissions in patients treated with 2-CDA. A 5 year survey. Leukemia 1997;11:629-32
   PubMed Web of Science ®Google Scholar
• Estey EM, Kurzrock R, Kantarjian HM, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CDA). Blood 1992;79:882-7
   PubMed Web of Science ®Google Scholar
• Jeh U, Barti R, Dietzfelbinger H, An update: 12 year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004;18:1476-81
   Google Scholar
• Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine. Response, toxicity and long-term follow-up. J Clin Oncol 1997;15:1138-42
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Variakojis D, A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992;9.2203-9
   Google Scholar
• Piro LD, Ellison JD, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadensine in the treatment of hairy cell leukemia. Leuk Lymph 1994;14:121-5
   PubMedGoogle Scholar
• Robak T, Jamroziak K, Gora-Taylor J, Cladribine in a weekly versus daily schedule for untreated hairy cell leukemia: final report for the Polish adult Leukemia Group (PALG) of a prspective randomised multicentre trial. Blood 2007;109:3672-5
   PubMed Web of Science ®Google Scholar
• Chada P, Rademaker AW, Mendiratta P, Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CDA): long-term follow-up of the Northwestern University experience. Blood 2005;106:241-6
   Google Scholar
• Arons E, Margulies I, Sorbara L, Minimal residual disease in hairy cell leukemia patients assessed by clone- specific polymerase chain reaction. Clin Cancer Res 2006;12:2804-11
   PubMed Web of Science ®Google Scholar
• Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunohistology specimens. Leuk Lymphoma 2011;52(Suppl 2):62-4
   PubMedGoogle Scholar
• Tallman MS. Implications of minimal residual disease in hairy cell leukemia after cladribine using immuno- histochemistry and immunophenotyping. Leuk Lymphoma 2011;52(Suppl 2):65-8. 644 645
   PubMedGoogle Scholar
• Lauria F, Lenoci M, Annino L, Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukaemia. Haematologica 2001;86:1046-50
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood 2003;102:810-13
   PubMed Web of Science ®Google Scholar
• Else M, Osuji N, Forconi F, The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukaemia. Cancer 2007;110:2240-7
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien S, Jorgensen J, Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011;118:3818-23
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011;52(Suppl 2):75-8
   Google Scholar
• Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood 2012;119:1988-91
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. Bio Drugs 2009;23:1-13
   Google Scholar
• Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 2006;20:1137-51
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Arons E, Stetler-Stevenson M, Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia Leuk Lymphoma. 2011;52(Suppl 2):82-6
   Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy cell leukemia. N Engl J Med 2001;345:241-7
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Robbins D, Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94:3340-8
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Phase I trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with B-cell malignancies. J.Clin. Oncol 2005;23:6719-29
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukaemia. J Clin Oncol 2009;27:293-2990
   Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17(20):6398-405
   PubMed Web of Science ®Google Scholar
• Bang S, Nagata S, Onda M, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11:1545-50
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Coutre S, Phase I dose-escalation study of CAT-8015 (HA22) a CD22 specific targeted immunotoxin in relapsed or refractory hairy cell leukemia (888 abstract). Blood 2009;114:366
   Google Scholar
• Kreitman RJ, Tallman MS, Robak T, Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30(15):1822-8
   PubMed Web of Science ®Google Scholar
• Dietrich S, Glimm H, Andrulis M, BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366(21):2038-40
   PubMed Web of Science ®Google Scholar